Glenmark Pharmaceuticals Ltd (GLENMARK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Glenmark Pharmaceuticals Ltd (GLENMARK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH29625D
  • |
  • Pages: 50
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Glenmark Pharmaceuticals Ltd (Glenmark) is a pharmaceutical company that focuses on the discovery of new chemical entities (NCEs) and new biological entities (NBEs). The company's formulations business encompasses therapeutic areas such as dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, central nervous system, and oncology. It also offers a wide range of generic products. The company manufactures and supplies active pharmaceutical ingredients (APIs). Glenmark developed a proprietary platform, Bispecific Engagement by Antibodies based on the T-cell receptor (BEAT) for production of bispecific antibodies for the treatment of HER2+ cancers. The company markets its products in North America, South America, Asia-Pacific and Africa. Glenmark is headquartered in Mumbai, Maharashtra, India.

Glenmark Pharmaceuticals Ltd (GLENMARK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Glenmark Pharmaceuticals Ltd, Medical Devices Deals, 2011 to YTD 2017 11

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Mayne Pharma Enters Into Distribution Agreement With Glenmark Pharma For Subacap 13

Glenmark Pharma Enters Into Co-Development Agreement With Forest Labs To Develop mPGES-1 Inhibitors 14

Glenmark Pharma Enters Into Distribution Agreement With Immanence Integral Dermo Correction 15

Licensing Agreements 16

Glenmark Pharma Enters into Licensing Agreement with Evestra for NuvaRing 16

Glenmark Pharma Enters into Licensing Agreement with Particle Sciences 16

Glenmark Generics Enters into Licensing Agreement with Celon Pharma 17

Equity Offering 18

Glenmark Pharma Raises USD151 Million in Private Placement of Shares 18

Glenmark Pharma Plans to Raise USD300 Million in Private Placement 19

Debt Offering 19

Glenmark Pharma Prices Private Placement of 4.5% Bonds for USD200 Million 19

Glenmark Pharma to Raise up to USD200 Million in Public Offering of Bonds 20

Glenmark Pharmaceuticals Ltd-Key Competitors 22

Key Employees 23

Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Recent Developments 28

Financial Announcements 28

Feb 02, 2017: Glenmark Pharmaceuticals Announces Quarter Results Ended December 31, 2016 28

Oct 27, 2016: Glenmark's consolidated revenue increases by 16.48% to Rs. 22241.09 Mn for Q2 FY 2016-17 29

Aug 12, 2016: Glenmark' s consolidated revenue increased by 18% to Rs. 19,430.52 Mn for Q1 FY 2016 -17 33

May 12, 2016: Glenmark's Consolidated Revenue for Q4 FY 2015-16 was at Rs. 23066.76 Mn recording an increase of 29.89% 34

Jan 28, 2016: Glenmark's Consolidated Net Profit increases by 48.38% to Rs. 1703 Mn in Q3 FY 15-16 38

Corporate Communications 39

Mar 31, 2017: Glenmark: Change in designation of Director 39

Oct 13, 2016: Glenmark Appoints Dr. Kurt Stoeckli as President and Chief Scientific Officer 40

May 12, 2016: Glenmark Appoints P. Ganeshi as Chief Finance Officer 41

Legal and Regulatory 42

Mar 15, 2017: Glenmark's Receives US FDA Approval For Ankleshwar plant 42

Feb 21, 2017: Glenmark Pharmaceuticals Provides Update On Ankleshwar Plant In Gujarat 43

Apr 21, 2016: Glenmark Provides Update On Pithampur Plant in Indore 44

Product Approvals 45

Apr 25, 2017: Glenmark Pharmaceuticals Initiates Clinical Investigation for GBR 310, its Proposed Biosimilar Candidate for XOLAIR 45

Apr 26, 2016: Glenmark Pharmaceuticals receives tentative ANDA approval for Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.01 mg, Ethinyl Estradiol Tablets USP, 0.01 mg and Ferrous Fumarate Tablets, 75 mg 46

Clinical Trials 47

Mar 08, 2017: Glenmark Pharmaceuticals Receives FDA Clearance of IND for GSP 304 47

Nov 04, 2016: Glenmark Pharmaceuticals Experimental GBR 1302-BEAT Demonstrates Potent Anti-Tumor Activity in Preclinical Data Presented at the ESMO Symposium on Immuno-Oncology 48

Other Significant Developments 49

Dec 19, 2016: Glenmark Unveils its Strategic Blueprint for Transition into an Innovation?Led Global Pharmaceutical Organization in the Next Decade 49

Appendix 50

Methodology 50

About GlobalData 50

Contact Us 50

Disclaimer 50

List of Figures

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Glenmark Pharmaceuticals Ltd, Medical Devices Deals, 2011 to YTD 2017 11

List of Tables

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Glenmark Pharmaceuticals Ltd, Deals By Therapy Area, 2011 to YTD 2017 9

Glenmark Pharmaceuticals Ltd, Medical Devices Deals, 2011 to YTD 2017 11

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

Mayne Pharma Enters Into Distribution Agreement With Glenmark Pharma For Subacap 13

Glenmark Pharma Enters Into Co-Development Agreement With Forest Labs To Develop mPGES-1 Inhibitors 14

Glenmark Pharma Enters Into Distribution Agreement With Immanence Integral Dermo Correction 15

Glenmark Pharma Enters into Licensing Agreement with Evestra for NuvaRing 16

Glenmark Pharma Enters into Licensing Agreement with Particle Sciences 16

Glenmark Generics Enters into Licensing Agreement with Celon Pharma 17

Glenmark Pharma Raises USD151 Million in Private Placement of Shares 18

Glenmark Pharma Plans to Raise USD300 Million in Private Placement 19

Glenmark Pharma Prices Private Placement of 4.5% Bonds for USD200 Million 19

Glenmark Pharma to Raise up to USD200 Million in Public Offering of Bonds 20

Glenmark Pharmaceuticals Ltd, Key Competitors 22

Glenmark Pharmaceuticals Ltd, Key Employees 23

Glenmark Pharmaceuticals Ltd, Other Locations 24

Glenmark Pharmaceuticals Ltd, Subsidiaries 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Glenmark Pharmaceuticals Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16145
Site License
USD 500 INR 32290
Corporate User License
USD 750 INR 48435

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com